Sangzin Ahn

Dr. Sangzin Ahn

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EYEun-Jeong Yang
Eun-Jeong Yang
SASangzin Ahn
Sangzin Ahn
JRJunghwa Ryu
Junghwa Ryu
MCMoon-Seok Choi
Moon-Seok Choi
SCShinkyu Choi
Shinkyu Choi
HKHye-Sun Kim
Hye-Sun Kim
Alzheimer’s disease (AD) is the most common form of dementia among the elderly. Neuritic plaques whose primary component is amyloid beta peptide (Aβ) and neurofibrillary tangles which are composed of hyperphosphorylated tau, are known to be the neuropathological hallmarks of AD. In addition, impaired synaptic plasticity in neuronal networks is thought to be important mechanism underlying for the cognitive deficits observed in AD. Although various causative factors, including excitotoxicity, mitochondrial dysregulation and oxidative damage caused by Aβ, are involved in early onset of AD, fundamental therapeutics that can modify the progression of this disease are not currently available. In the present study, we investigated whether phloroglucinol (1, 3, 5—trihydroxybenzene), a component of phlorotannins, which are plentiful in Ecklonia cava, a marine brown alga species, displays therapeutic activities in AD. We found that phloroglucinol attenuates the increase in reactive oxygen species (ROS) accumulation induced by oligomeric Aβ1–42 (Aβ1–42) treatment in HT-22, hippocampal cell line. In addition, phloroglucinol was shown to ameliorate the reduction in dendritic spine density induced by Aβ1–42 treatment in rat primary hippocampal neuron cultures. We also found that the administration of phloroglucinol to the hippocampal region attenuated the impairments in cognitive dysfunction observed in 22-week-old 5XFAD (Tg6799) mice, which are used as an AD animal model. These results indicate that phloroglucinol displays therapeutic potential for AD by reducing the cellular ROS levels.

1 March 2023 in Korean Journal of Medical Education
Verified
Journal Article
Open access
PDF file
SASangzin Ahn
Sangzin Ahn

1 January 2023 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
JGJong-Lyul Ghim
Jong-Lyul Ghim
SASangzin Ahn
Sangzin Ahn
Ghim JL, et al. Transl Clin Pharmacol. 2023 Sep;31(3):131-138. https://doi.org/10.12793/tcp.2023.31.e16

25 February 2016 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JRJ Ryu
J Ryu
BHB-H Hong
B-H Hong
YKY-J Kim
Y-J Kim
EYE-J Yang
E-J Yang
MCM Choi
M Choi
HKHye-Sun Kim
Hye-Sun Kim
The neuregulin (NRG) family of epidermal growth factor-related proteins is composed of a wide variety of soluble and membrane-bound proteins that exert their effects via the tyrosine kinase receptors ErbB2-ErbB4. In the nervous system, the functions of NRG1 are essential for peripheral myelination, the establishment and maintenance of neuromuscular and sensorimotor systems and the plasticity of cortical neuronal circuits. In the present study, we report that an intracerebroventricular infusion of NRG1 attenuated cognitive impairments in 13-month-old Tg2576 mice, an animal model of Alzheimer’s disease (AD). In addition, according to Golgi-Cox staining, NRG1 rescued the reduction in the number of dendritic spines detected in the brains of Tg2576 mice compared with vehicle (PBS)-infused mice. This result was also corroborated in vitro as NRG1 attenuated the oligomeric amyloid beta peptide1-42 (Aβ1-42)-induced decrease in dendritic spine density in rat primary hippocampal neuron cultures. NRG1 also alleviated the decrease in neural differentiation induced by oligomeric Aβ1-42 in mouse fetal neural stem cells. Collectively, these results suggest that NRG1 has a therapeutic potential for AD by alleviating the reductions in dendritic spine density and neurogenesis found in AD brains.

1 September 2024 in The Korean Journal of Physiology & Pharmacology
Verified
Journal Article
Open access
PDF file
SASangzin Ahn
Sangzin Ahn
Sangzin Ahn. Korean J Physiol Pharmacol 2024;28:393-401. https://doi.org/10.4196/kjpp.2024.28.5.393

1 February 2018 in Pharmacological Research
Verified
Journal Article
Open access
UMUsman Mahmood
Usman Mahmood
SASangzin Ahn
Sangzin Ahn
EYEun-Jeong Yang
Eun-Jeong Yang
MCMoonseok Choi
Moonseok Choi
HKHyunju Kim
Hyunju Kim
HKHye-Sun Kim
Hye-Sun Kim
Mounting evidence suggests that the etiology of autism spectrum disorders (ASDs) is profoundly influenced by exposure to environmental factors, although the precise molecular and cellular links remain ill-defined. In this study, we examined how exposure to valproic acid (VPA) during pregnancy is associated with an increased incidence of ASD. A mouse model was established by injecting VPA at embryonic day 13, and its behavioral phenotypes including impaired social interaction, increased repetitive behaviors and decreased nociception were observed at postnatal days 21-42. VPA-treated mice showed dysregulation of synaptic structure in cortical neurons, including a reduced proportion of filopodium-type and stubby spines and increased proportions of thin and mushroom-type spines, along with a decreased spine head size. We also found that VPA-treatment led to decreased expression of phosphate and tensin homolog (PTEN) and increased levels of p-AKT protein in the hippocampus and cortex. Our data suggest that there is a correlation between VPA exposure and dysregulation of PTEN with ASD-like behavioral and neuroanatomical changes, and this may be a potential mechanism of VPA-induced ASD.